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Abstract
As an important tumor suppressor protein, reactivate mutated p53 was found in many kinds of human cancers and that
restoring active p53 would lead to tumor regression. In this work, we developed a new computational method to predict
the transcriptional activity for one-, two-, three- and four-site p53 mutants, respectively. With the approach from the general
form of pseudo amino acid composition, we used eight types of features to represent the mutation and then selected the
optimal prediction features based on the maximum relevance, minimum redundancy, and incremental feature selection
methods. The Mathew’s correlation coefficients (MCC) obtained by using nearest neighbor algorithm and jackknife cross
validation for one-, two-, three- and four-site p53 mutants were 0.678, 0.314, 0.705, and 0.907, respectively. It was revealed
by the further optimal feature set analysis that the 2D (two-dimensional) structure features composed the largest part of the
optimal feature set and maybe played the most important roles in all four types of p53 mutant active status prediction. It
was also demonstrated by the optimal feature sets, especially those at the top level, that the 3D structure features,
conservation, physicochemical and biochemical properties of amino acid near the mutation site, also played quite
important roles for p53 mutant active status prediction. Our study has provided a new and promising approach for finding
functionally important sites and the relevant features for in-depth study of p53 protein and its action mechanism.
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Introduction
As a critical tumor suppressor gene, p53 plays an important role
in maintaining genomic stability and preventing cancer [1,2,3]. It
has the highest mutation frequency in human tumors: over 50% of
kinds of tumors have p53 mutations, and over 80% of kinds of
tumors involve dysfunctional p53 signaling pathway [4]. It was
reported that restoring p53 activity could lead to tumour
regression and that p53 mutants could be reactivate in vivo
through intragenic second-site suppressor mutations. In view of
this, it is worthwhile for us to conduct an in-depth study on the
occurrence of p53 mutation because the findings thus obtained
may provide useful insights for developing new drugs that possess
similar functions of ‘‘cancer rescue’’ via mutation as p53 does.
P53 gene encodes a 393 amino-acid protein which contains
three important domains: an amino-terminal transactivation
domain, a core domain which recognizes p53 DNA binding sites,
and a carboxy-terminal tetramerization domain [5,6]. About 75%
of mutations are single amino acid substitutions in the core domain
[7]. There are three (not mutually exclusive) kinds of outcomes
when p53 mutation occurs [8,9]. The first kind of mutation is to
destroy the function of tumour suppressor for the affected allele of
p53; if both alleles are mutated, the cells will completely loss the
capacity of anticancer protection provided by p53. The second
kind of mutation is to make the mutant p53 dominate the wild-
type p53 by forming inactive mixed tetramers so as to deprive the
ability of binding to DNA and transactivation. Therefore, even
with one wild-type allele mutated, the cell may practically loss of
the wild-type p53 function. The last kind of mutation is to make
the mutant p53 gain or enhance its function for tumour
progression [8,9]. In other words, different kinds of p53 mutations
may have completely different impacts to cancer patients.
Accordingly, knowing mutant functional properties across a
mutation sequence space is of specific interest that could advance
medical practice. However, mutation spaces grow to be combi-
natorially large and hence making it time-consuming and labour-
intensive for experimental studies. The resources for such
experimental studies may also be quite limited. In view of this, it
is important and urgent to develop computational approaches for
studying the effects of different kinds of mutation or mutation-
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effects.
The present study was devoted to develop a new computational
method for predicting the active status of one-, two-, three- and
four site p53 mutants. Our method used eight types of features: (1)
gain/loss of amino acids during evolution [10] and conservation of
amino acid at protein-protein interface [11]; (2) physicochemical
and biochemical properties of amino acid, i.e., the ‘‘amino acid
factors’’; (3) conservation; (4) structural disorder; (5) distance
between mutations; (6) the physicochemical differences between
the original amino acid and the new amino acid at the mutation
site; (7) 2D structure surface of the mutant protein; (8) 3D structure
changes of the p53 protein caused by the mutation. The optimal
features were selected based on the Maximum Relevance &
Minimum Redundancy (mRMR) and Incremental Feature
Selection (IFS). The Mathew’s correlation coefficients (MCC)
obtained by using Nearest Neighbor Algorithm (NNA) and
jackknife cross validation for one-, two-, three- and four- site
p53 mutants were 0.678, 0.314, 0.705 and 0.907, respectively. It
has been revealed through further optimal feature set analysis that
the 2D structure features composed the largest part of the optimal
feature set and played the most important roles in all these four
types of p53 mutant active status prediction. It has also been
demonstrated via analysing the optimal feature sets, especially
those at the top level, that the 3D structure features, PSSM
conservation features and amino acid factor features played
important roles in p53 mutant active status prediction.
According to a recent comprehensive review [12], to establish a
really useful statistical predictor for a protein or peptide system, we
need to consider the following procedures: (i) construct or select a
valid benchmark dataset to train and test the predictor; (ii)
formulate the protein or peptide samples with an effective
mathematical expression that can truly reflect their intrinsic
correlation with the attribute to be predicted; (iii) introduce or
develop a powerful algorithm (or engine) to operate the prediction;
(iv) properly perform cross-validation tests to objectively evaluate
the anticipated accuracy of the predictor. Below, let us describe
how to deal with these steps.
Materials and Methods
Dataset
We downloaded the mutant p53 transcriptional activity data set
from UCI Machine Learning Repository http://archive.ics.uci.
edu/ml/datasets/p53+Mutants [13,14,15]. After filtering the
mutations that could not be encoded, there were 62 one-site
mutations (7 active ones, 55 inactive ones), 16372 two-site
mutations (57 active ones, 16315 inactive ones), 111 three-site
mutations (63 active ones, 48 inactive ones) and 31 four-site
mutations (7 active ones, 24 inactive ones). We used the following
eight types of features to encode the mutation site and its
upstream/downstream four amino acids.
As mentioned above, to develop a powerful predictor for a
protein or peptide system, one of the keys is to formulate the
protein or peptide samples with an effective mathematical
expression or vector that can truly reflect their intrinsic correlation
with the target to be predicted. To realize this, let us utilize the
general form of pseudo amino acid composition (PseAAC) [16]
that can be formulated as follows [12]
P~ y1 y2 ::: yu ::: yV ½ 
T ð1Þ
where T is a transpose operator, while the subscript V reflects the
dimension of the vector and its value as well as the components y1,
y2, … will be defined by a series of feature extractions as
elaborated below.
Type 1 features: gain/loss of amino acids during
evolution and conservation of amino acid at protein-
protein interface
Let us consider the following two kinds of features: one
representing the gain/loss of amino acids during evolution [10]
(we called ‘‘SNP’’ feature for short), and the other representing
conservation of amino acid at protein-protein interface [11]
(hereafter it will be abbreviated as ‘‘pro-pro’’ feature) for each
amino acid in each 9 amino-acid peptide. The SNP feature of
gain/loss of amino acids during evolution was calculated based on
the normalized differences between the number of substitutions
creating and removing the amino acid [10]. The pro-pro feature of
conservation of amino acid at protein-protein interface was
calculated based on the number of conserved residues of this kind
of amino acid at the contact interface, the total number of residues
of this kind of amino acid in the protein, and the number of total
amino acids in the protein [11]. It represents the conservation
propensities on the binding sites [11].
Type 2 features: physicochemical and biochemical
features of amino acid
The diversity and specificity of protein structures and functions
are largely attributed to the different compositions of different
amino acids, which have different physicochemical properties.
Atchley et al. [17] have performed multivariate statistical analyses
on AAIndex [18] that is a database of various amino acid
physicochemical and biochemical properties. These authors have
summarized and transformed AAIndex to five highly compact
numeric patterns to reflect the polarity (Factor 1), secondary
structure (Factor 2), molecular volume (Factor 3), codon diversity
(Factor 4), and electrostatic charge (Factor 5). In the current study,
these five numerical pattern scores (abbreviated as ‘‘amino acid
factors’’ or ‘‘AAFactor’’) are used to represent the respective
properties of each amino acid. Thus, there are 5 AAFactor
features for each of the amino acids in a 9 amino-acid peptide.
Type 3 features: conservation of residues
The position specific iterative BLAST (PSI BLAST) [19] was
adopted to quantify the conservation probabilities of an amino acid
against the 20 different types of native amino acids by using a 20D
vector. All such 20D vectors for all residues in a given protein
sequence formed the position specific scoring matrix (PSSM).
Residues, which are more important for biological function, are
more conserved through cycles of PSI BLAST. There are 20 PSSM
features for each of the amino acids in a 9 amino-acid peptide.
Type 4 features: structural disorder
The VSL2 [20] was used to score the structural disorder of each
amino acid in the protein sequence. Protein disordered region is a
segment that lacks 3D structures under physiological conditions
and plays important roles in signalling control and regulation.
There is one disorder feature for each of the amino acids in a 9
amino-acid peptide.
Type 5 features: distance between mutation sites
In human mammary carcinoma, the mutation sites of p53 tend
to occur within one single exon away or a short distance from
another [21], implying that the distance of mutations may be of
importance for affecting the function of p53. Here, we used 1, 2, 3
distance features for two-, three- and four-site p53 mutants
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adjacency mutations. For example, in three-site mutants, there
were 2 distance features, which were the distance from the first
mutant site to the second one, and the distance from the second to
the third. Other distance features were defined in a similar way.
Type 6 features: the physicochemical differences
between the original amino acid and the new amino acid
at the mutation site
The GRANTHAM score [22] was adopted to measure the
physicochemical differences between two amino acids. According
to such a score, if two amino acids have similar physicochemical
features, the mutation from one to another will not cause the
change of protein functions. There is one GRANTHAM feature
for each mutant site.
Type 7 features: 2D structure features
The structure features for each mutant were calculated based on
the homology models [14,15]. The structures of mutant proteins
were simulated based on the structure of wild type p53 with
mutant amino acids substituted. Then structure features were
extracted from the energy minimized mutant model [13]. The
attributes 1–4826 of structure features (V1–V4826) were calculat-
ed based on the 2D surface map of the mutant protein [13,14,15]
where it is available for molecular interactions or drug binding.
Type 8 features: 3D structure features
Attributes 4827–5408 (V4827–V5408) of structure features
were calculated based on the 3D distance difference map between
mutant and wild-type p53 [13,14,15]. Mutation of amino acid in
p53 may change the 3D structure of protein. The 3D distance map
of p53 protein is an N6N matrix showing the distance between N
residue alpha carbons [15]. It reflects the structural changes
caused by the mutation of amino acids. After subtracting the
distance map of wild-type p53, a difference map was obtained.
The 3D distance difference map features represent the magnitudes
of the distance changes in 3D structure. Both the 2D structure
features and 3D structure features were downloaded from UCI
Machine Learning Repository http://archive.ics.uci.edu/ml/
datasets/p53+Mutants [13,14,15].
Feature space for one-site, two-site, three-site and four-
site mutants
Shown in Table 1 is a breakdown of the number of each kind of
features for one-site, two-site, three-site and four-site mutants,
respectively. Accordingly, we totally have 1z1z5z20z ð f
1Þ|9z1z1z1z5z4826z582g~5668 features for a 9 amino
acid peptide with one-site mutant. Similarly, we have 1z1 ð ½ f
z5z20z1Þ|9z1z1z1z5) |2z1z4826z582g~5929,
1z1z5z20z1 ðÞ |9z1z1z1z5 ½  |3z2z4826z582 fg ~
6190, and 1z1z5z20z1 ðÞ |9z1z1z1z5 ½  |4z3z f
4826z582g~6451 features for a 9 amino acid peptide with one-
site, two-site, and four-site mutants, respectively. Accordingly, the
dimension V for a 9 amino acid peptide mutant as formulated by
equation (1) can now be expressed by
V~
5668, forone   sitemutant
5929, fortwo   sitemutant
6190, forthree   sitemutant
6451, forfour   sitemutant
8
> > > <
> > > :
ð2Þ
Thus, substituting the dimension value for V as well as the value
for each of relevant features as described above into equation (1),
we immediately obtain the 5668D, 5929D, 6190D, or 6451D
vector for the one-site, two-site, three-site, or four-site mutant of 9
amino acid peptide, respectively. The vectors thus obtained will be
used to represent the statistical samples concerned for the current
study.
mRMR method
To rank the features with their importance, we used the
maximum relevance minimum redundancy (mRMR) method
developed by by Peng et al. [23]. The mRMR program can be
downloaded from http://penglab.janelia.org/proj/mRMR/. It
recursively selects the feature that has the maximum relevance to
the target variable and minimum redundancy to the already
selected features. Features that have a smaller index mean that
they are selected earlier and are more important. We used the
mutual information (MI) to quantify the relation between two
vectors, which was defined as follows
Ix ,y ðÞ ~
ÐÐ
px ,y ðÞ log
px ,y ðÞ
px ðÞ py ðÞ
dxdy ð3Þ
In equation (3), x and ydenote vectors; px ðÞ and py ðÞ denote the
marginal probabilistic densities; and px ,y ðÞ denotes joint proba-
bilistic density.
To quantify both relevance and redundancy, we defined V as
the whole feature set, Vs as the already-selected feature set
containing m features and Vt as the to-be-selected feature set
containing n features. The relevance D between feature f in Vt
and the target c can be calculated by:
D~If ,c ðÞ ð 4Þ
The redundancy R between the feature f in Vt and all the features
in Vs can be calculated by:
R~
1
m
X
fi[Vs
If ,fi ðÞ ð 5Þ
The mRMR function, which combined equation (4) and equation
(5) and can be used to obtain the feature fj in Vt with maximum
relevance and minimum redundancy, was defined as following:
max
fj[Vt
If j,c
  
{
1
m
X
fi[Vs
If j,fi
  
2
4
3
5 j~1,2,:::,n ðÞ ð 6Þ
Given a feature set with NN ~mzn ðÞ features, the feature
evaluation will be performed N rounds. After these evaluations,
mRMR method will generate a feature set S:
S~ f
0
1,f
0
2,:::,f
0
h,:::,f
0
N
no
ð7Þ
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round the feature is selected. A better feature will be selected
earlier and have a smaller index h.
Nearest Neighbor Algorithm
We used nearest neighbor algorithm (NNA) [12] to build the
prediction model of p53 activity. NNA calculates similarities
between the test sample and all the training samples. In the current
study, the distance between vector px and py is defined as
following [24,25,26,27,28,29,30,31]:
Dp x,py
  
~1{
px:py
px kk : py
        ð8Þ
In equation (8), px:py denotes the inner product of px and py.
p kk denotes the module of vectorp. The smaller Dp x,py
  
is, the
more similar px to py is.
In NNA, given a vector ptand training set P~ p1, f
p2,:::,pn,:::,pNg, pt will be designated to the same class of its
Figure 1. The IFS curves for one-site, two-site, three-site and four-site p53 mutants. In the IFS curve, the x-axis is the number of features
used for classification, and the y-axis is the Mathew’s correlation coefficients (MCC) generated by the jackknife test. (A) The IFS curve for one-site p53
mutants. The peak of MCC is 0.678 with 8 features. The top 8 features derived by the mRMR approach form the optimal feature set for one-site p53
mutants. (B) The IFS curve for two-site p53 mutants. The peak of MCC is 0.314 with 50 features. The top 50 features derived by the mRMR approach
form the optimal feature set for two-site p53 mutants. (C) The IFS curve for three-site p53 mutants. The peak of MCC is 0.705 with 282 features. The
top 282 features derived from the mRMR approach form the optimal feature set for three-site p53 mutants. (D) The IFS curve for four-site p53
mutants. The peak of MCC is 0.907 with 25 features. The top 25 features derived from the mRMR approach form the optimal feature set for four-site
p53 mutants.
doi:10.1371/journal.pone.0022940.g001
Predicting Activity of Multiple Site p53 Mutants
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22940nearest neighbor pn in P, i.e. the vector having the smallest
Dp n,pt ðÞ :
Dp n,pt ðÞ ~minDp 1,pt ðÞ ,Dp 2,pt ðÞ ,:::,Dp z,pt ðÞ ,:::,Dp N,pt ðÞ fg z = t ðÞ ð 9Þ
Jackknife Cross-Validation Method
In statistical prediction, the following three cross-validation
methods are often used to examine a predictor for its effectiveness
in practical application: independent dataset test, subsampling test,
and jackknife test [32]. However, as elucidated in [33] and
demonstrated by Eqs.28–32 of [12], among the three cross-
validation methods, the jackknife test is deemed the least arbitrary
that can always yield a unique result for a given benchmark
dataset, and hence has been increasingly used and widely
recognized by investigators to examine the accuracy of various
predictors (see, e.g., [34,35,36,37,38,39,40,41]). Accordingly, in
this study we also used the jackknife test to evaluate the
performance of our classifier. In the jackknife cross-validation,
each of the statistical samples in the benchmark dataset is in turn
singled out as a tested sample and the predictor is trained by the
remaining samples. During the jackknifing process, both the
training dataset and testing dataset are actually open, and a
statistical sample will in turn move from one to the other. The
jackknife cross-validation can exclude the memory effects during
entire testing process and also the result thus obtained is always
unique for a given benchmark dataset [25].
Since the positive and negative samples are highly imbalanced in the
data set, the Matthews’s correlation coefficient (MCC) [42] was used to
evaluate the prediction performance and its definition is given by
MCC~
TP | TN{FP| FN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TPzFN ðÞ |TNzFP ðÞ |TPzFP ðÞ |TNzFN ðÞ
p ð10Þ
w h e r eT P ,T N ,F Pa n dF Nw e r et h en u m b e ro ft r u ea c t i v em u t a n t s ,
true inactive mutants, false active mutants and false inactive mutants,
respectively [43].
Incremental Feature Selection
With features ranked by mRMR method, incremental feature
selection (IFS) was applied to determine the optimal number of
features [26,27,28,29,30,44]. An incremental feature selection is
conducted for each of the independent predictor with the ranked
features. Features in a set are added one by one from higher to
lower rank. If one feature is added, a new feature set is obtained,
then we get N feature sets, and the i-th feature set is:
Si~ f1,f2,:::,fi fg 1ƒiƒN ðÞ ð 11Þ
where N is the number of features. With each of the N feature sets,
an NNA predictor was constructed and tested using Jackknife
cross-validation test. With MCC of jackknife cross-validation
calculated, we obtain an IFS table with the number of features and
the performance of them. Soptimal is the optimal feature set that
achieves the highest MCC.
Results
mRMR result
Using the mRMR program, we obtained the ranked mRMR list
of 5668, 5929, 6190 and 6451 features for one-, two-, three- and
four-site p53 mutants respectively (cf. Eq.2). Within the lists, the
smaller index of a feature indicates it has a more important role in
discriminating positive samples from negative ones. The mRMR
lists were used in IFS procedure for further feature selection and
analysis.
IFS result
Based on the outputs of mRMR, we built individual predictors
by adding features recursively from the top of the mRMR output
to the bottom to predict the active status of p53 mutants. We
tested each of the individual predictors and obtained the IFS
results. The IFS results for one-, two-, three- and four-site p53
mutants are provided as Table S1, Table S2, Table S3 and Table
S4, respectively. The IFS curves for one-site, two-site, three-site
and four-site p53 mutants were shown in Figure 1.
Optimal feature set analysis for one-site p53 mutants
Figure 1 A shows IFS curve plotted based on Table S1. The
maximum MCC is 0.678 by using 8 features as shown in Table 2.
Within the optimal feature set for one-site p53 mutants active
status prediction, there are two 2D structure features (V241 and
V78), three PSSM features (i.e., AA3_PSSM-8-G: the conservation
status against G at residue 3; AA8_PSSM-19-Y: the conservation
Table 1. Number of features for one-site, two-site, three-site and four-site mutants.
Features One-site mutant Two-site mutant Three-site mutant Four-site mutant
SNP features
a 169+1=10 (1 69+1)62=20 (1 69+1)63=30 (1 69+1)64=40
Pro-pro features
b 169+1=10 (1 69+1)62=20 (1 69+1)63=30 (1 69+1)64=40
Amino acid factor 569+5=50 (5 69+5)62=100 (5 69+5)63=150 (569+5)64=200
PSSM features 2069=180 206962=360 20 6963=540 20 6964=720
Disorder feature 169=9 1 6962=18 1 6963=27 1 6964=36
GRANTHAM 1 2 3 4
Distance features 0 1 2 3
2D structure features 4826 4826 4826 4826
3D structure features 582 582 582 582
Total 5668 5929 6190 6451
aGain/loss of amino acids during evolution.
bConservation of amino acid at protein-protein interface.
doi:10.1371/journal.pone.0022940.t001
Predicting Activity of Multiple Site p53 Mutants
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e22940status against Y at residue 8; and AA2_PSSM-18-W: the
conservation status against W at residue 2), two AAFactor features
(AA6_AAFactor-3: the molecular volume amino acid factor feature
at residue 6; AA5_AAFactor-1: the polarity amino acid factor
feature at residue 6) and one disorder feature at residue 4.
Optimal feature set analysis for two-site p53 mutants
Shown in Figure 1 B is the IFS curve plotted based on Table S2.
The maximum MCC is 0.314 by using 50 features. The 50 optimal
features for the two-site p53 mutants are given in Table S5.
Within the top 50 features, there are 49 2D structure features
and 1 PSSM feature (AP2.AA8_PSSM-3-N). Listed in Table 3 are
the top 10 features for two-site p53 mutants. The conservation
status against N at residue 8 is the top feature within the selected
optimal feature set, indicating that site 8 and the specific mutation
status against N plays the most important role in determining the
active status of two-site p53 mutants. The inclusion of 49 2D
structure features within the optimal 50 features indicates its
important roles. As mentioned in introduction, the majority of p53
mutations occurred in the core DNA-binding domain [7]. Within
the DNA-binding domain of p53 protein, the secondary structures
(the two alpha-helices and the eleven beta-strands) were
susceptible to amino acid substitution [45]. Thus, the changes of
secondary structures would alter the DNA contact and Zn binding
so as to cause functional changes [45].
Optimal feature set analysis for three-site p53 mutants
Shown in Figure 1 C is the IFS curve plotted based on Table
S3. The maximum MCC is 0.705 using 282 features although it
can reach 0.632 already with the top 48 features. The 282 optimal
features for three-site p53 mutants are provided in Table S6.
There are totally 249 structure features (including 214 2D features,
35 3D structure features), 22 PSSM features, 7 AAFactor features,
1 SNP feature, 2 disorder features, and 1 pro-pro feature.
The top 10 features for active status prediction of three-site p53
mutants are shown in Table 4. There are 7 2D structure features
(including the Top four features), indicating that they have the
most important impact on the three-site p53 mutants active status
prediction. The fifth feature is the polarity amino acid factor
feature at residue 2 and mutation site 1 (AP1.AA2_AAFactor-1).
This indicates that residue 2 at mutation site 1, especially its
polarity property, would play an important role for the active
status prediction of three-site p53 mutants. The 3D structure
features (index 6 and 8) may also play some roles for this type of
prediction.
There are 18, 9, and 6 optimal features at mutation site 1, 2,
and 3, respectively. For more detailed information about these
optimal features, please refer to Table S7, S8 and S9, respectively.
Optimal feature set analysis for four-site p53 mutants
As we can see from Figure 1 D, the MCC reached the
maximum value (0.907) when using 25 features shown in Table 5.
In the optimal feature set there are three AP1 features
(AP1.AA9_PSSM-7-E, AP1.AA2_PSSM-11-L, and AP1.AA2_AA-
Factor-4) as well as one AP2 feature (AP2.AA1_PSSM-14-F),
indicating that these specific features at relevant residues may play
more roles than other features and residues.
The optimal feature set also contains 19 2D structure features
and 2 3D structure features (including the top 8 features), which is
fully consistent with the majority of this optimal feature set (21/
25), indicating that these two types of features would play
important roles in the four-site p53 mutant active status prediction.
Comparison of the optimal feature sets of the four types
of p53 mutants
By comparison of the optimal feature sets for one-, two-, three-
and four-site p53 mutants, we can now see that the 2D structure
features composed the largest part of the optimal feature set and
hence might play the most important roles in all these four types of
p53 mutant active status prediction. It has also been demonstrated
Table 4. Top 10 features for three-site p53 mutants.
Order Name Score
1 V2261 0.159
2 V3291 0.074
3 V4391 0.069
4 V3106 0.067
5 AP1.AA2_AAFactor-1 0.056
6 V5068 0.061
7 V4075 0.049
8 V5278 0.046
9 V3568 0.05
10 V3978 0.052
doi:10.1371/journal.pone.0022940.t004
Table 2. Optimal feature set for one-site p53 mutants.
Order Name Score
1 AA3_PSSM-8-G 0.144
2 AA8_PSSM-19-Y 0.105
3 V241 0.067
4 AA6_AAFactor-3 0.052
5 V78 0.05
6 AA5_AAFactor-1 0.04
7 AA2_PSSM-18-W 0.039
8 AA4_disorder 0.04
doi:10.1371/journal.pone.0022940.t002
Table 3. Top 10 features for two-site p53 mutants.
Order Name Score
1 AP2.AA8_PSSM-3-N 0.004
2 V1152 0.002
3 V55 0.002
4 V1854 0.001
5 V4001 0
6 V2846 0
7 V4168 0
8 V1059 0
9 V2633 0
10 V3105 0
doi:10.1371/journal.pone.0022940.t003
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that the 3D structure features, PSSM conservation features and
AAFactor features did play important roles in p53 mutant active
status prediction. The selected optimal feature sets, especially those
at the top level, may provide important clues or insights for further
experimental studies in this area.
Discussion
The relationship between structure change and function
change in p53 mutants
It was found through this study that most of the selected features
were those directly related to structure. The relationship between
structure and function of p53 were suspected for quite a long time.
Most cancer-associated p53 amino acid mutations are located at
the highly conserved central DNA binding domain, suggesting a
correlation between the evolutionary conservation and the
structural or functional importance of amino acid residues
[45,46]. It has been reported [45,47] that those residues, which
are in contacting with DNA or located at the opposite side of
DNA, would form the core of the folded protein, and hence are
most likely to be conserved and mutated. Most hotspots with high
evolutionary conservation are either near to the DNA-protein
interface, or at the amino acids in contacting with DNA [45,47].
Mutation of cysteines 176, 238 and 242 to serine within the zinc
region will completely block the transcriptional activation of p53
[48]. It is evidenced that mutation of arginine 156, arginine 158,
serine 215 and glutamate 258 in p53 protein will destabilize the
protein structure [45,48] owing to the repulsion interactions
between the side chains of these amino acids.
The imbalance of features from different sites in
multiple-site p53 mutants
It has been observed through this study that the selected features
of multiple-site p53 mutants are usually located on only part of the
mutation sites. This is probably due to the reason that the
unselected mutation sites might contribute nothing to the p53
functional abnormality because the selected mutation sites, which
serve as ‘‘hitch-hikers’’ [49], have already done the job.
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